A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Genentech, Inc.
Study ID
NCT01301716
Phase
PHASE1
Status
Completed

Conditions

  • Solid Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GDC-0980 — DRUG
    Oral escalating dose
  • bevacizumab — DRUG
    Intravenous repeating dose
  • carboplatin — DRUG
    Intravenous repeating dose
  • cisplatin — DRUG
    intravenous repeating dose
  • paclitaxel — DRUG
    Intravenous repeating dose
  • pemetrexed — DRUG
    intravenous repeating dose

Study Details

This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid tumors.

Key Dates

First listed
Feb 23, 2011
Start date
Sep 30, 2011
Status verified
Nov 2016
Primary completion
Aug 31, 2014
Completion
Aug 31, 2014

Study Design

Enrollment
75 participants (actual)
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
  • Experimental: B
  • Experimental: C

Primary Outcome Measure

Incidence of adverse events [ Time Frame: Up to 30 days after last dose of study treatment or initiation of new anti-cancer therapy, whichever comes first ]

Locations (4)

FacilityCityStateZIPSite coordinators
-Los AngelesCalifornia90025-
-TampaFlorida33612-
-BostonMassachusetts02114-
-BostonMassachusetts02215-

Related Studies